Conexeu Sciences (NASDAQ:CNXU – Get Free Report) and Nanovibronix (NASDAQ:FEED – Get Free Report) are both small-cap manufacturing companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.
Valuation & Earnings
This table compares Conexeu Sciences and Nanovibronix”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Conexeu Sciences | N/A | N/A | N/A | N/A | N/A |
| Nanovibronix | $2.55 million | 1.22 | -$18.18 million | ($8.82) | -0.06 |
Insider and Institutional Ownership
16.4% of Nanovibronix shares are held by institutional investors. 5.2% of Nanovibronix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Conexeu Sciences and Nanovibronix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Conexeu Sciences | N/A | N/A | N/A |
| Nanovibronix | -923.20% | -54.25% | -43.10% |
Analyst Ratings
This is a summary of current recommendations and price targets for Conexeu Sciences and Nanovibronix, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Conexeu Sciences | 0 | 1 | 1 | 0 | 2.50 |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
Conexeu Sciences currently has a consensus target price of $20.00, indicating a potential upside of 110.75%. Given Conexeu Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Conexeu Sciences is more favorable than Nanovibronix.
Summary
Conexeu Sciences beats Nanovibronix on 6 of the 9 factors compared between the two stocks.
About Conexeu Sciences
Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University’s right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company’s only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix (“ECM”) formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the “10 Minute Tissue™” concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration (“FDA”) clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
Receive News & Ratings for Conexeu Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conexeu Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
